Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ultragenyx Pharma (RARE) PT Lowered to $70 at JMP Securities
February 21, 2018 4:35 AM ESTJMP Securities lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining a Market Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Lowered to $74 at Stifel
February 21, 2018 3:32 AM ESTStifel lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $74.00 (from $85.00) while maintaining a Buy rating.
... MoreUltragenyx Pharma (RARE) Tops Q4 EPS by 10c
February 20, 2018 4:12 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More